TNF receptor action modulation

Details TNF receptor action modulation TNF receptor action modulation

1993-05-03

2002-05-28

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Lymphokine

C435S007100, C530S351000

Reexamination Certificate

active

06395267

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to the modulation of signal transduction by the tumor necrosis factor receptors (TNF-Rs) and to modulation of the cleavage of these TNF-Rs. More particularly, the invention provides peptides and other substances which interact either with the TNF-Rs, or with effector proteins interacting with the receptor, and thus can be employed for prophylactic and therapeutic applications in diseases associated with the function of TNF.
BACKGROUND OF THE INVENTION
TNF, a pro-inflammatory cytokine produced primarily by macrophages, contributes to the defense of the host against pathogens as well as to various detrimental manifestations of inflammation through a variety of different effects on cell function (Old, 1990; Beutler and Cerami, 1989). These effects are initiated by the binding of TNF to specific, high affinity cell surface receptors (TNF-Rs), expressed on most kinds of cells (Baglioni et al., 1985; Beutler et al., 1985; Kull et al., 1985; Tsujimoto et al., 1985; Aggarwal et al., 1985; Israel et al., 1986). The receptors provide the intracellular signals for cell response to TNF (Engelmann et al., 1990a). Two molecular species of the TNF-Rs, the p55 and the p75 TNF-R, expressed differentially in different types of cells, have been identified (Engelmann et al., 1990b; Brockhaus et al., 1990).
One of the most distinct characteristics of TNF compared to other immune system mediators is its ability to elicit cell death. In many severe diseases, such as autoimmune disorders, rheumatoid arthritis, graft rejection, and graft-versus-host disease, TNF seems to be a major cause for pathological tissue destruction. Blocking TNF activity in these conditions is therefore of the highest importance for the development of new therapies for these diseases.
On the other hand, in certain other situations it is advantageous to augment the function of TNF, e.g. in situations where its anti-tumor or antibacterial activities are beneficial.
The main mediator for the cytotoxic effect of TNF on fibroblastoid and epithelial cells is the p55 TNF-R, which also is the prevalent TNF-R type on these cell lines. Blocking this receptor species abolishes, the cytocidal effect of TNF, while inducing aggregation of the receptor molecules can mimic the cytocidal effect of TNF.
The soluble form of this receptor, as well as the soluble form of the other (p75) TNF-R, have been shown to have inhibitory effects on TNF function. Evidence was presented that these soluble forms are derived proteolytically from the cell surface forms, (Nophar et al., 1990; Porteu and Nathan, 1990; Porteu et al., 1991).
Both the signaling by the receptors and the cleavage of the receptors appear to reflect interactions between the receptor and some cellular effector proteins; the cleavage—by interacting with regulatable proteases, and the signaling—by interacting with proteins having some signaling activity.
SUMMARY OF THE INVENTION
The present invention provides a method of modulating signal transduction and/or cleavage in tumor necrosis factor receptors (TNF-Rs) comprising interfering with one or more amino acids in the sequence of a TNF-R or with an effector protein interacting with the TNF-R.
This interference influences the normal functioning of the TNF-Rs or influences an effector protein interacting therewith, and thereby modulates signal transduction by causing partial or total inhibition thereof, or influences shedding, i.e., abolishes cleavage of the soluble form of the receptor.
The present invention further provides peptides or other molecules which interact either with the receptor itself, i.e., interact with one or more amino acids in the receptor sequence, or interact with the effector proteins, and thus modulate the normal functioning of the TNF-Rs. The above molecules also include antibodies or fragments thereof.
The peptides and other substances may either be produced by conventional or by recombinant methods.
The invention also provides pharmaceutical compositions comprising the above peptides or other substances for treatment of TNF related disorders.


REFERENCES:
Engelmann et al 1990 J. Biol. Chem 265(24)): 14497-14504.*
Lie et al 1992 Biochem Brophys Res. Commun 188(2): 503-509.*
Espevik et al 1990 J. Exp. Med. 171: 415-426.*
BNA's Patent, Trademark & Copy Mgmt Journal 53: 419-421.*
Bharat B. Aggarwal, Structure of Tumor Necrosis Factor and its Receptor, Biotherapy, vol. 3, pp. 113-120, 1991.
M.R. Shalaby et al, Binding and Regulation of Cellular Functions . . . Receptors, J.Exp.Med., vol. 172, pp. 1517-1520, Nov. 1990.
Hwang et al, A 20 Amino Acid Synthetic Peptide of a Region . . . in Vitro, Proceedings of the Royal Society of London, vol. 245, No. 1313, pp. 85-158, Aug. 22, 1991.

Affiliated with

Also associated with

Rating

TNF receptor action modulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TNF receptor action modulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF receptor action modulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2875899